Saugatuck Therapeutics

Saugatuck Therapeutics Ltd has acquired an exclusive license from Yale University for use of the NLG platform for delivering DNA aptamers and certain aptamer-based combination products.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]